期刊文献+

胸腺素α1-胸腺五肽在大肠杆菌中的表达及表达条件优化 被引量:4

Expression and optimization of expression conditions of Tα1-TP5 fusion peptide in E.coli
下载PDF
导出
摘要 目的探讨胸腺素α1-胸腺五肽(Tα1-TP5)在大肠杆菌中的表达及表达条件优化。方法将化学合成的Tα1-TP5基因与原核表达载体pGEX-4T-1融合并转化至E.coliBL21(DE3),异丙基-β-D-硫代半乳糖苷(IPTG)诱导表达。利用SDS-PAGE电泳和AlphaEase凝胶电泳图像分析系统研究培养基组成、诱导时机、诱导温度、诱导剂浓度及诱导时间等条件对融合蛋白表达量的影响。融合蛋白经GST琼脂糖珠亲和色谱纯化及重组肠激酶切割后,电喷雾质谱鉴定Tα1-TP5。结果选用TB培养基,在菌体对数生长中后期加入终浓度为0.05 mmol/L的IPTG,37℃诱导5 h,GST融合蛋白的表达量最高,占菌体总蛋白的35.8%,且主要以可溶形式表达。Tα1-TP5的分子质量与理论值相似。结论 Tα1-TP5成功在E.coli中表达,并确定了最佳表达条件。 Purpose To investigate the expression of Tα1-TP5 fusion peptide and optimization of the expression conditions.Methods The chemically synthesized Tα1-TP5 gene was fused with prokaryotic expression vector pGEX-4T-1 and transformed into E.coli BL21(DE3),subsequently induced by IPTG.SDS-PAGE electrophoresis and AlphaEase gel electrophoresis image analysis system were used to analyze the influence of culture medium,induction starting time,induction temperature,inducer concentration and induction time on the expression level of target protein.GST fusion protein was purified by GST sepharose and cut by recombinant enterokinase.Tα1-TP5 was identified by ESI-MS.Results When using TB as the medium and adding final concentration of 0.05 mmol/L of IPTG into the middle and late logarithmic phase of bacteria to induce for 5 h at 37 ℃,the expression of GST fusion protein was the highest,accounting for 35.8% of the bacterial total protein,and mainly in a soluble form.Identified by ESI-MS,the molecular weight of Tα1-TP5 was identical with theoretical value.Conclusion Tα1-TP5 has been successfully expressed in E.coli and the expression conditions of the GST fusion protein were optimized.
出处 《中国生化药物杂志》 CAS CSCD 北大核心 2011年第4期265-268,共4页 Chinese Journal of Biochemical Pharmaceutics
关键词 胸腺素α1-胸腺五肽 胸腺融合肽 GST融合蛋白 大肠杆菌 表达条件 Tα1-TP5 fusion peptide GST fusion protein E.coli expression conditions.
  • 相关文献

参考文献3

  • 1Sugahara S, Ichida T, Yamagiwa S, et al. Thymosin-alphal increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B[J]. Hepatol Res,2002,24(4) :346-354.
  • 2Sasaki H, Fujii Y, Masaoka A, et al. Elevatedplasma thymosinaI- phal levels in lung cancer patients [J]. Eur J Cardiothorac Surg, 1997,12(6) :885-891.
  • 3Gao D, Zhang X, Zhang J, et al. Expression of thymosin ctl-thymo- pentin fusion peptide in Pichia pastoris and its characterization [ J]. Arch Pharm Res,2008,31 ( 11 ) :1471-1476.

同被引文献26

  • 1仲立军,刘淑燕,曹强庚,刘洪庆.胸腺肽的临床应用概况[J].中国药业,2004,13(11):76-77. 被引量:5
  • 2Jobe A, Bourgeois S. Lac repressor-operator interaction. VI. The natural inducer of the lacoperon [ J ]. J Mol Biol, 1972,69 ( 3 ) : 397-404.
  • 3Knutsen AP, Freeman JJ, Mueller KR, et al. Thymosin-alphal stimulates maturation of CD34 + stem ceils into CD3 + 4 + cells in anin vitrothymic epithelia organ coculture model [ J ]. Int J Immunopharmacol, 1999,21 ( 1 ) : 15 - 26.
  • 4Ancel CD, Phipps J, Young L. Thymosin alpha 1 [ M]. Am J Heahh-Syst-Pharm, 2001,58:879 - 885.
  • 5Salvati F, Rasi G, Portalone L, et al. Combined treatment with thymosin-alphal and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial [ J ]. Antieancer-Res, 1996,16 (2) : 1001 - 1004.
  • 6Ramaehandran R, Katzenstein DA, Winters MA, et al. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodefieiency virus type 1 infection [ J ]. J Infect Dis, 1996,173(4) :1005 - 1008.
  • 7Knutsen AP,Freeman JJ,Mueller KR,et al.Thymosin-alpha 1stimulates maturation of CD34+stem cells into CD3+4+cells in anin vitro thymic epithelia organ coculture model.Int J Immun-opharmacol,1999,21(1):15-26.
  • 8Ancel CD,Phipps J,Young L.Thymosin alpha 1.Am J HealthSyst Pharm,2001,58(10):879-885.
  • 9Salvati F,Rasi G,Portalone L,et al.Combined treatment withthymosin-alpha 1 and low-dose interferon-alpha after ifosfamide innon-small cell lung cancer:a phase-Ⅱcontrolled trial.Antican-cer-Res,1996,16(2):1001-1004.
  • 10Ramachandran R,Katzenstein DA,Winters MA,et al.Polyeth-ylene glycol-modified interleukin-2 and thymosin alpha 1 inhuman immunodeficiency virus type 1 infection.J Infect Dis,1996,173(4):1005-1008.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部